


ENDORPHIN AND PROLACTIN LEVELS IN SCHIZOPHRENIC PATIENTS UNDER  
NEUROLEPTIC THERAPY



By  
Bahar A.A.E. Massoud

M.B. B.Ch. M.Sc. Internal Medicine

Thesis Submitted as a Partial Fulfillment of Doctorate of Medicine  
Faculty of Medicine  
Ain Shams University

Supervised by

Prof. Abdel Mottal Kabil  
Professor of Medicine  
Ain Shams University


Prof. Mustafa Kamel Ismail  
Professor of Psychiatry  
Ain Shams University

Prof. S.M. Raafat  
Professor of Medicine  
Ain Shams University

Dr. Mohamed Fahmy  
Assistant Professor of Medicine  
Ain Shams University

Dr. Mohamed Shanon  
Lecturer in Psychiatry  
Ain Shams University

1991



وَعَلَّمَكَ مَا لَمْ تَكُن تَعْلَمُ

وَكَانَ فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا

صَوَّدَ وَاللَّهُ الْعَظِيمُ

سورة النساء آية ١١٣



## TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT .....	i
LIST OF FIGURES .....	ii
LIST OF TABLES .....	iii
INTRODUCTION .....	2
AIM OF THE WORK .....	5
REVIEW OF LITERATURE .....	7
(1) Schizophrenia .....	7
(2) Biochemistry of Opioid Peptides .....	25
(3) Physiological Aspects .....	
(4) Neuropeptides in Schizophrenia .....	61
(5) Dopaminergic Systems and Schizophrenia .....	88
SUBJECTS AND METHODS .....	107
RESULTS AND TABLES .....	124
DISCUSSION .....	148
SUMMARY AND CONCLUSION .....	161
RECOMMENDATIONS .....	164
REFERENCES .....	165
LIST OF ABBREVIATIONS .....	177
CLINICAL DATA SHEET .....	179
ARABIC SUMMARY .....	

## ACKNOWLEDGEMENT

I would like to express my deepest appreciation and gratitude to Prof. Abou El Maati Nabih, Prof. of Medicine for his constructive guidance, continuous help, and encouragement throughout the development of this work.

I am also greatly indebted to Prof. Moustafa Kamel Ismail, Professor of Psychiatry, Ain Shams University for his help and guidance in selecting and planning for this work particularly from the psychiatric aspect.

I also wish to thank Prof. Sayed Raafat, Professor of Medicine, Ain Shams University for his support and encouragement during the course of this work and also for his valuable comments concerning many points of clinical interest.

I am also thankful to Dr. Mohamed Fahmy, Assistant Professor of Medicine, for his endless encouragement which helped in accomplishing this work.

To Dr. Mohamed Ghanem, Lecturer of Psychiatry, Ain Shams University, I would like to express my deepest gratitude and respect for the valuable discussions and endless encouragement which helped guide me in selecting the cases and writing the literature.

May I also express my deepest appreciation and gratitude to Prof. Mohamed Shaarawy, Professor of Biochemistry and Head of Gynecological Endocrinology and Maternal Biochemistry Laboratories, Dept. of Obstet. & Gynecol., Cairo University and to members of his unit for their help in bioassaying and providing the results of endorphin and prolactin levels in blood. I would also like to thank Prof. Shaarawy for his guidance in evaluating the statistical data and preparing these results.

I would also like to thank Dr. Mohsen Gadallah, Assistant Professor of Community Medicine, Ain Shams University, for his help in revising the statistical data and tabulating the results and for his valuable comments concerning the study as a whole.

I would like to thank Prof. Hussein El Dammasy, Professor of Medicine, Ain Shams University, for making it possible for us to import all material needed for the bioassay of  $\beta$ -endorphin and prolactin.

Lastly but not least, I am indebted to Mr. Aziz Kirollos from the Engineering Department of the American University in Cairo, for his help in typing and preparing this manuscript.

LIST OF FIGURES

	Page
Fig. 1 Important anatomical structures in the brain	1
Fig. 2 History of schizophrenia	6
Fig. 3 Drawings of schizophrenic patient	9
Fig. 4 Four schizophrenic identical twins	13
Fig. 5 Hebephrenic schizophrenia	14
Fig. 6 Catatonic schizophrenia	14
Fig. 7 Schizophrenic art	15
Fig. 8 Structure of opiate peptide	26
Fig. 9 Composition of two enkephalins	28
Fig. 10 Biological relationship between three prohormones coding for enkephalins	30
Fig. 11 Opiate receptors in spinal cord	35
Fig. 12 Regional distribution of peptides in CNS	39
Fig. 13 Opiate receptors in pig brain	41
Fig. 14 Opiate receptors and pain perception	50
Fig. 15 Opiate neurons and substance-P	51
Fig. 16 Three-dimensional structures of Met-Enk and morphine	64
Fig. 17 Regional concentrations of endorphins in CNS	69
Fig. 18 Opiate and enkephalin receptors in comparison	73
Fig. 19 Endorphins in rat hypothalamus	79
Fig. 20 Chemical structures of opiate agonists and antagonists	84
Fig. 21 Dopamine pathways in brain	89
Fig. 22 Chlorpromazine and dopamine	90
Fig. 23 Connections of the limbic system	92
Fig. 24 Dopamine receptors and neuroleptic drugs	93

## LIST OF TABLES

	Page
Table 1 Schizophrenic syndromes	21
Table 2 Diagnostic features of residual schizophrenia	22
Table 3 Diagnostic features of schizoaffective disorders	22
Table 4 Diagnostic features of paramoid schizophrenia	23
Table 5 Diagnostic features of undifferentiated schizophrenia	23
Table 6 Diagnostic features of catatonic schizophrenia	24
Table 7 Diagnostic features of hebephrenic schizophrenia	24
Table 8 Neuropeptides in the brain	62
Table 9 Comparison between aminergic and peptidergic systems	63




Fig. 1 Important anatomical structures in the human brain (from drugs and the brain, Snyder, S.H., p. 17, 1986).

## **INTRODUCTION**

## INTRODUCTION

In insanity we do not discover anything new or unknown; we are looking at the foundations of our own being, the matrix of those vital problems on which we are all engaged ... it makes no difference to the facts whether these disturbances are called dementia praecox or by some other name [172].

The symptoms of what is now called Schizophrenia have fascinated physicians and philosophers for thousands of years. However, the search for the causes and the cures of Schizophrenic manifestations was impeded by the fact that what is now known as Schizophrenia was not even described as a disease entity until 1896, when Emil Kraepelin [102] brought together, under the term dementia praecox, a variety of psychotic syndromes previously believed to represent separate diseases.

The Schizophrenias are a group of psychoses, the course of which is at times chronic, at times marked by intermittent attacks, which can remit at any stage, but probably never without leaving behind some defect of personality. The disease is characterized by a specific type of alteration of thinking, feeling and relation to the external world [172].

Many theories as to the possible cause or causes of Schizophrenia have been put forward. But there are insufficient data to decide which is the correct theory [94]. One of the theories suggests that the symptoms of Schizophrenia maybe due to alterations in the usual relationships between neurotransmitters. But this alone cannot explain the whole pathophysiology of the syndrome [94].

Neurotransmitters are chemical substances that transfer information in the C.N.S. and peripheral nervous system and establish intercellular communication. It is at this point where neuropsychiatry and neuroendocrinology meet. Between 1927 and 1975 less than 10 neurotransmitters were discovered. In 1984, this number has risen to more than 50 [168].

Most research in the field of psychiatry in general and Schizophrenia in particular has focused on the monoamine neurotransmitters. Recently, this focus has shifted to the peptide neurotransmitters, particularly to the opioid peptides, the endorphins [94].

A study by Davis [40] revealed a significant clinical improvement in Schizophrenics receiving naloxone. This might point to a role played by opioid peptides in the pathophysiology of Schizophrenia.

The greatest stimulus for research into neuropeptide neurobiology was the discovery that the various endocrine axes are organized in an hierachical fashion, with the C.N.S. at the summit. The chemical regulation, the releasing and inhibiting factors, are now known to be neuropeptides. The<sup>sc</sup> findings have not only resulted in major diagnostic and therapeutic breakthroughs in clinical endocrinology, but have had considerable impact on the field of psychiatry as well. It is now becoming more evident that particular psychiatric disorders are often associated with robust and reproducible neuroendocrine abnormalities [140].

Neuropeptides are important neuroregulators in the C.N.S. They function as neurotransmitters and neuromodulators and,

consequently, they also modulate behaviour. Moreover, some evidence is concordant with the view that alterations of specific neuropeptide - containing neurons occur in certain neuropsychiatric disorders, including Schizophrenia [140].

At the present time, the data provided by measuring opioid peptides in both plasma and C.S.F. are contradictory and confusing and provide no compelling evidence for a significant role of endorphins in Schizophrenia [140].

Considerable evidence points to the involvement of dopamine, as a C.N.S. neurotransmitter, in the pathophysiology of schizophrenia and other psychoses [106].

The direct measurement of dopaminergic activity in the human brain is not presently possible. Because the secretion of the anterior pituitary hormone prolactin is under tonic inhibition of a specific C.N.S. dopaminergic system, measurement of prolactin secretion has been used as an index of dopamine activity in Schizophrenia and its response to neuroleptic therapy [160].

**AIM OF THE WORK**

AIM OF THE WORK

Alterations in Dopaminergic and peptidergic system functioning are thought to contribute to the pathogenesis of Schizophrenic psychosis.

The aim of our work is to study the changes in blood levels of  $\beta$ -endorphin and prolactin (as an index of dopaminergic system functioning) that occur in patients suffering from Schizophrenia before and after treatment using neuroleptic drugs and whether these changes have any clinical significance whether it maybe diagnostic or prognostic. Most research has been performed in foreign countries. Our study will be conducted on Egyptian patients.




Fig. 1 Historical growth and varieties of classification of the schizophrenia concept. (Kaplan & Saddock, edit. Modern synopsis of comprehensive Textbook of Psychiatry/III, 1981; W.W., Baltimore, London).